Related Experiment Video

Updated: Aug 17, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Effects of carvedilol upon intra- and interventricular synchrony in patients with chronic heart failure

Pablo F Castro1, Paul Mc-Nab, Juan Carlos Quintana

  • 1Faculty of Medicine, P. Catholic University of Chile, University of Chile, Santiago, Chile. pcastro@med.puc.cl

The American Journal of Cardiology
|July 16, 2005
PubMed

Insights

Carvedilol improved heart contraction synchrony in heart failure (HF) patients. This treatment reduced ventricular dyssynchrony and left ventricular (LV) volumes, enhancing cardiac function.

Area of Science:

  • Cardiology
  • Nuclear Medicine
  • Pharmacology

Background:

  • Heart failure (HF) is often associated with impaired cardiac function.
  • Ventricular dyssynchrony is a common finding in patients with heart failure.
  • Assessing and improving ventricular synchrony is crucial for HF management.

Purpose of the Study:

  • To evaluate the effect of carvedilol on left ventricular (LV) and interventricular contraction synchrony in stable heart failure patients.
  • To determine if improvements in synchrony correlate with changes in LV volumes.

Main Methods:

  • Radionuclide isotopic ventriculography with phase analysis was used.
  • 30 patients with stable heart failure were studied.
  • Measurements were taken at baseline and after 6 months of maximal tolerated carvedilol treatment.

Main Results:

  • Patients with heart failure exhibited significant ventricular dyssynchrony compared to a normal population.
  • Carvedilol treatment led to significant improvement in ventricular synchrony in patients with the greatest baseline dyssynchrony.
  • Improved synchrony positively correlated with a reduction in end-diastolic LV volumes.

Conclusions:

  • Carvedilol can improve ventricular synchrony in heart failure patients.
  • The reduction in ventricular dyssynchrony is associated with beneficial changes in LV volumes.
  • These findings suggest carvedilol's potential role in managing cardiac synchrony in HF.

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...